Cardiorenal Metabolic Syndrome: How Heart, Kidney and Metabolic Health Are Linked

What if heart disease, kidney disease and diabetes weren’t separate diseases at all?

For decades, these conditions have been treated independently. But research now shows they are closely interconnected. Problems that begin with excess body fat or insulin resistance can gradually affect the kidneys, while declining kidney function can place additional strain on the heart. Rather than existing in isolation, each condition can fuel the progression of the others.

This concept is known as Cardiorenal Metabolic Syndrome (CKM Syndrome), a framework that recognises the heart, kidneys and metabolic system as part of one interconnected network. Understanding this relationship allows doctors to identify risk earlier, intervene sooner and reduce the likelihood of serious complications such as heart attack, stroke, heart failure and chronic kidney disease.

In this article, we'll explain what Cardiorenal Metabolic Syndrome is, why it matters and how protecting one organ often means protecting them all.

Cardiorenal Metabolic Syndrome at a Glance

What is cardiorenal metabolic syndrome?

Cardiorenal Metabolic Syndrome (CKM Syndrome) [1], also known as Cardiovascular-Kidney-Metabolic Syndrome, is a term used to describe the close relationship between cardiovascular disease, kidney disease and metabolic disorders such as obesity, insulin resistance and type 2 diabetes. It reflects the understanding that these conditions are not isolated health problems but are interconnected through shared risk factors and biological processes.

Traditionally, heart disease, kidney disease and metabolic disorders have been managed as separate conditions. However, growing evidence has shown that dysfunction in one area often affects the others [2]. For example, obesity and insulin resistance can increase the risk of high blood pressure and type 2 diabetes, both of which can damage the heart and kidneys over time [3]. Similarly, kidney disease can increase cardiovascular risk [4], while heart disease can contribute to declining kidney function [5]. These interactions have prompted a more integrated approach to understanding and managing chronic disease.

Cardiorenal Metabolic Syndrome places emphasis on identifying and addressing risk factors early, before significant organ damage occurs. By recognising the links between metabolic, cardiovascular and kidney health, healthcare professionals can take a more comprehensive approach to prevention, risk assessment and treatment.

How are the heart, kidneys and metabolic system connected?

Cardiorenal Metabolic Syndrome develops because the heart, kidneys and metabolic system constantly influence one another. Changes affecting one system can trigger a chain reaction that impacts the others, creating a cycle of progressive disease.

Early warning signs to look out for

One of the challenges of Cardiorenal Metabolic Syndrome is that it often develops gradually and may not cause obvious symptoms in its early stages. In many cases, the first signs are detected through routine health screenings rather than physical symptoms.

Potential early warning signs include:

• Increasing waist circumference or central weight gain
• Elevated blood pressure readings
• Rising fasting blood glucose or HbA1c levels
• Abnormal cholesterol or triglyceride levels
• Fatty liver detected on imaging
• Protein or albumin detected in the urine
• Declining kidney function on blood tests
• Reduced exercise tolerance
• Persistent fatigue or low energy levels

As the condition progresses, some individuals may develop symptoms related to cardiovascular or kidney disease, including swelling in the ankles, shortness of breath, chest discomfort or changes in urinary habits. However, many people remain symptom-free until significant disease has already developed, highlighting the importance of regular health screening.

The stages of cardiorenal metabolic syndrome

Cardiorenal Metabolic Syndrome develops along a continuum rather than appearing suddenly. To help identify risk earlier and guide preventive care, the American Heart Association (AHA) has proposed a staging system that reflects the progression from optimal health to established cardiovascular disease [21].

Importantly, progression through these stages is not inevitable. Early identification of risk factors and appropriate intervention can slow disease progression and, in some cases, prevent advancement to more severe stages.

How is cardiorenal metabolic syndrome diagnosed?

There is no single test that confirms Cardiorenal Metabolic Syndrome. Diagnosis involves evaluating multiple aspects of cardiovascular, kidney and metabolic health to identify risk factors and determine the extent of disease.

• Medical History and Risk Assessment  — A healthcare professional will review personal and family medical history, current health conditions, lifestyle factors and any symptoms that may suggest cardiovascular, metabolic or kidney-related disease.
• Blood Pressure Measurement  — Blood pressure is a key component of cardiometabolic health. Persistently elevated readings can indicate increased cardiovascular and kidney disease risk.
• Blood Tests  — Several blood tests may be performed to assess metabolic and kidney function, including:
  • HbA1c to evaluate long-term blood sugar control
  • Fasting blood glucose to identify prediabetes or diabetes 
  • Fasting insulin levels to identify insulin resistance prior to prediabetes
  • Lipid profile to assess cholesterol and triglyceride levels
  • Kidney function tests such as serum creatinine and estimated glomerular filtration rate (eGFR)
• Urine Testing  — Urine tests can detect the presence of protein or albumin, which may indicate early kidney damage before symptoms become apparent.
• Body Composition Assessment  — Measurements such as body mass index (BMI), waist circumference and body fat distribution help assess obesity-related risk and metabolic health. At the metabolic clinic we prefer DEXA body composition scans.
• Cardiovascular Risk Evaluation  — Additional investigations may be recommended depending on an individual’s risk profile. These may include cardiovascular imaging, electrocardiography (ECG) or other assessments used to evaluate heart and vascular health.

How is cardiorenal metabolic syndrome treated?

Treatment aims to reduce overall disease risk by addressing cardiovascular, kidney and metabolic health simultaneously. Management plans are tailored to the individual's health profile and risk factors.

• Lifestyle and Nutrition Changes  — Lifestyle modification forms the foundation of treatment. A balanced dietary pattern that supports healthy weight management, blood sugar control and cardiovascular health is often recommended.
• Weight Management  — For individuals who are overweight or obese, achieving and maintaining a healthy weight can improve metabolic function, lower blood pressure and reduce strain on the cardiovascular and renal systems.
• Physical Activity — Regular exercise supports cardiovascular fitness, improves insulin sensitivity and contributes to better overall metabolic health. Physical activity recommendations should be tailored to individual abilities and medical conditions.
• Blood Sugar Management — Effective control of blood glucose levels helps reduce the risk of diabetes-related complications and protects both cardiovascular and kidney health.
• Blood Pressure Control — Maintaining healthy blood pressure levels is important for reducing strain on the heart and minimising kidney damage.
• Cholesterol Management — Improving cholesterol and triglyceride levels can help lower the risk of atherosclerosis and cardiovascular disease.
• Medications — Depending on an individual's risk profile and existing medical conditions, medications may be prescribed to manage blood pressure, blood sugar, cholesterol levels or kidney disease. Newer therapies may provide benefits across multiple aspects of cardiometabolic health and the use of these medications such as GLP-1 Agonists and SGLT-2 inhibitors have revolutionised cardiorenal metabolic syndrome by addressing route causes.

When should you visit an Endocrinologist?

Consider seeing an endocrinologist if you have one or more risk factors for Cardiorenal Metabolic Syndrome, particularly if lifestyle changes alone have not been enough to improve your health. Early assessment can help identify metabolic abnormalities before they progress to cardiovascular or kidney disease.

You should consider scheduling an appointment if you:

• Have overweight or obesity, particularly excess abdominal fat.
• Have prediabetes or type 2 diabetes.
• Have persistently elevated blood pressure or abnormal cholesterol levels.
• Have insulin resistance or metabolic syndrome.
• Have abnormal kidney function or protein detected in your urine.
• Have fatty liver disease alongside metabolic risk factors.
• Have a family history of type 2 diabetes, cardiovascular disease or chronic kidney disease.
• Are struggling to lose weight despite consistent diet and exercise.
• Have been diagnosed with one cardiometabolic condition and would like a comprehensive assessment of your overall cardiovascular, kidney and metabolic health.

Early intervention may help slow disease progression, reduce the risk of long-term complications and support better heart, kidney and metabolic health.

Summary

Cardiorenal Metabolic Syndrome recognises that the heart, kidneys and metabolic system are closely interconnected. Risk factors such as obesity, insulin resistance, high blood pressure and abnormal cholesterol can affect multiple organ systems simultaneously, increasing the likelihood of heart disease, chronic kidney disease and other long-term complications. Early identification and management can help slow disease progression and improve long-term health outcomes.

If you have concerns about your weight, blood sugar, blood pressure, cholesterol or kidney health, or have multiple cardiometabolic risk factors, consider booking a consultation with the team at The Metabolic Clinic. A personalised assessment can help identify your risk factors and develop a tailored management plan to support your long-term cardiovascular, kidney and metabolic health.

References 

1. Singh, A., Kesani, H., Verma, S., Saleh, T. M., & Rai, M. (n.d.). Cardio-renal metabolic syndrome: An integrated approach to prevention and management. Cureus, 17(10), e94134. https://doi.org/10.7759/cureus.94134 
2. Tanasescu, M.-D., Rosu, A.-M., Minca, A., Rosu, A.-L., Grigorie, M.-M., Timofte, D., & Ionescu, D. (2026). Metabolic dysfunction at the core: Revisiting the overlap of cardiovascular, renal, hepatic, and endocrine disorders. Life, 16(1), 172. https://doi.org/10.3390/life16010172 
3. Wondmkun, Y. T. (2020). Obesity, insulin resistance, and type 2 diabetes: Associations and therapeutic implications. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 13, 3611–3616. https://doi.org/10.2147/DMSO.S275898 
4. Said, S., & Hernandez, G. T. (2014). The link between chronic kidney disease and cardiovascular disease. Journal of Nephropathology, 3(3), 99–104. https://doi.org/10.12860/jnp.2014.19 
5. Heart disease & kidney disease—Niddk. National Institute of Diabetes and Digestive and Kidney Diseases. Retrieved June 25, 2026, from https://www.niddk.nih.gov/health-information/kidney-disease/heart-disease  
6. Choo, Y. N., Ravi, R. N., & Subramaniyan, V. (2026). Insulin resistance induced by obesity: Mechanisms, metabolic implications and therapeutic approaches. Molecular Biology Reports, 53(1), 357. https://doi.org/10.1007/s11033-026-11509-3 
7. Jha, R., Lopez-Trevino, S., Kankanamalage, H. R., & Jha, J. C. (2024). Diabetes and renal complications: An overview on pathophysiology, biomarkers and therapeutic interventions. Biomedicines, 12(5), 1098. https://doi.org/10.3390/biomedicines12051098 
8. Hall, M. E., do Carmo, J. M., da Silva, A. A., Juncos, L. A., Wang, Z., & Hall, J. E. (2014). Obesity, hypertension, and chronic kidney disease. International Journal of Nephrology and Renovascular Disease, 7, 75–88. https://doi.org/10.2147/IJNRD.S39739 
9. Heart and kidney disease: Connection, causes, symptoms, and treatment options | national kidney foundation. Retrieved June 25, 2026, from https://www.kidney.org/kidney-topics/heart-and-kidney-connection 
10. CDC. (2025, August 13). Chronic kidney disease, diabetes, and heart disease. Chronic Kidney Disease. https://www.cdc.gov/kidney-disease/risk-factors/link-between-diabetes-and-heart-disease.html 
11. Wang, Z., & Nakayama, T. (2010). Inflammation, a link between obesity and cardiovascular disease. Mediators of Inflammation, 2010, 535918. https://doi.org/10.1155/2010/535918 
12. Health threats from high blood pressure. Www.Heart.Org. Retrieved June 25, 2026, from https://www.heart.org/en/health-topics/high-blood-pressure/health-threats-from-high-blood-pressure  
13. Pappan, N., Awosika, A. O., & Rehman, A. (2026). Dyslipidemia. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK560891/ 
14. Chronic kidney disease (Ckd)—Symptoms, causes, treatment | National Kidney Foundation. (Retrieved June 25, 2026, from https://www.kidney.org/kidney-topics/chronic-kidney-disease-ckd 
15. Health risks of overweight & obesity. National Institute of Diabetes and Digestive and Kidney Diseases. Retrieved June 25, 2026, from https://www.niddk.nih.gov/health-information/weight-management/adult-overweight-obesity/health-risks 
16. Xing, Y., Yang, X., & Zhao, Q. (n.d.). The association between family history of hypertension and diabetic kidney disease in patients with diabetes: A cross-sectional study. Frontiers in Endocrinology, 17, 1774744. https://doi.org/10.3389/fendo.2026.1774744 
17. Zhang, J., Huang, H., Lin, Z., Dong, J., Zhang, X., Gao, J., Liu, Y., Li, C., & Cui, Z. (2025). Associations between cardiovascular-kidney-metabolic syndrome and disability in activities of daily living: A nationwide longitudinal study among the middle-aged and older adults in China. Frontiers in Public Health, 12, 1480576. https://doi.org/10.3389/fpubh.2024.1480576 
18. Godoy-Matos, A. F., Valério, C. M., Júnior, W. S. S., de Araujo-Neto, J. M., Sposito, A. C., & Suassuna, J. H. R. (2025). CARDIAL-MS (Cardio-renal-diabetes-liver-metabolic syndrome): A new proposition for an integrated multisystem metabolic disease. Diabetology & Metabolic Syndrome, 17, 218. https://doi.org/10.1186/s13098-025-01796-4 
19. Alhindal, M., Janahi, J., D’Angelo, E. C., Lisignoli, V., Palmieri, R., Cutrì, A., Butera, G., Gatzoulis, M. A., & Montanaro, C. (2025). Impact of smoking on cardiovascular health: Mechanisms, epidemiology and specific concerns regarding congenital heart disease. International Journal of Cardiology Congenital Heart Disease, 20, 100581. https://doi.org/10.1016/j.ijcchd.2025.100581 
20. Jean-Louis, G., Zizi, F., Clark, L. T., Brown, C. D., & McFarlane, S. I. (2008). Obstructive sleep apnea and cardiovascular disease: Role of the metabolic syndrome and its components. Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine, 4(3), 261–272. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2546461/ 
21.  Lassen, M. C. H., Ostrominski, J. W., Claggett, B. L., Ndumele, C. E., Biering-Sørensen, T., Matsushita, K., Selvin, E., Coresh, J., Shah, A., Solomon, S. D., & Vaduganathan, M. (2026). Cardiovascular–kidney–metabolic syndrome stages, echocardiographic characteristics, and heart failure risk: The atherosclerosis risk in communities study. Circulation, 153(17), 1268–1280. https://doi.org/10.1161/CIRCULATIONAHA.125.077894